ArticleACS biomaterials science & engineering2025
Therapeutic Potential of Rose Hip-Derived Nanoparticles for Psoriatic Skin Inflammation.
Article in ACS biomaterials science & engineering, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Can Microneedle-Nanocarrier Platforms Deliver True Tolerogenic Immunotherapy for Psoriasis?Vaccines · 2026Review
- Past, Present, and Future of Plant-Derived Extracellular Vesicles in Biomedical Applications.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Potential Enhancement of Topical Drug Delivery Using Grapefruit-derived Nanoparticles Modified Using TAT Peptide.Pharmaceutical research · 2026Article
- Exosomes in Psoriasis: From Pathogenic Mechanisms to Therapeutic Innovations.Clinical, cosmetic and investigational dermatology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriasis is a chronic skin disease characterized by hyperproliferation of keratinocytes and excessive inflammation. Plant-derived nanoparticles (pdNPs) are promising agents for treating inflammatory skin diseases. In this study, we examined the characteristics and functions of rose hip-derived nanoparticles (RNPs) rich in various bioactive compounds. RNPs were isolated from rose hips using sucrose ultracentrifugation and characterized using NanoSight and transmission electron microscopy. Cellular uptake by HaCaT human keratinocytes was analyzed using flow cytometry and confocal microscopy. Uptake mechanisms were investigated using siRNA knockdown. Proliferation, apoptosis, and cytokine expression were evaluated in a HaCaT psoriasis model. Antioxidant activity was assessed by measuring reactive oxygen species (ROS) levels in stimulated HaCaT and RAW264.7 mouse macrophage-like cells. The in vivo efficacy was evaluated in a mouse model of psoriasis via intradermal injection of RNPs. The RNPs obtained via ultracentrifugation exhibited a vesicular structure of approximately 100 nm in diameter. They were efficiently taken up by HaCaT cells and inhibited excessive inflammation-induced proliferation. RNPs reduced the mRNA levels of the inflammatory cytokines, interleukin-1β and interferon-γ. Additionally, RNPs were efficiently internalized by mouse macrophage-like RAW264.7 cells, decreasing the intracellular reactive oxygen species levels. The intradermal injection of RNPs effectively suppressed epidermal hyperproliferation and macrophage infiltration in an imiquimod-induced psoriasis mouse model. Collectively, these results suggest that RNPs can be used to treat psoriasis by regulating oxidative stress and inhibiting epidermal hyperproliferation. RNPs, which exerted potent effects on epidermal cells, target key pathological mechanisms such as oxidative stress and immune-driven keratinocyte proliferation. Therefore, they are promising natural therapeutic agents for psoriasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.